Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib

Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway, which plays a key role in the underlying pathophysiology of myeloproliferative diseases. We describe a case of...

Descripción completa

Detalles Bibliográficos
Autores principales: Abidi, Maheen Z., Haque, Javeria, Varma, Parvathi, Olteanu, Horatiu, Guru Murthy, Guru Subramanian, Dhakal, Binod, Hari, Parameswaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097796/
https://www.ncbi.nlm.nih.gov/pubmed/27843657
http://dx.doi.org/10.1155/2016/2389038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097796/
https://www.ncbi.nlm.nih.gov/pubmed/27843657
http://dx.doi.org/10.1155/2016/2389038

Ejemplares similares